
Alphatec Hlds (ATEC) Stock Forecast & Price Target
Alphatec Hlds (ATEC) Analyst Ratings
Bulls say
Alphatec Holdings is expected to experience significant growth due to its sales force expansion, new product launches, market share gains, and increasing number of products sold per procedure. This is supported by the company's strong financial performance with a 20-21% YoY revenue growth in Q4 2025 and a 24% increase in surgical volume. Furthermore, the acquisition of exclusive distribution rights for OsteoAdapt, a next-generation biologics product, can potentially enhance the company's spinal portfolio and attract more surgeon users. With the company's positive outlook, we reiterate our Buy rating and set a 12-month price target of $22, based on an EV/sales multiple of 4.2x our 2026E revenue estimate.
Bears say
Alphatec Holdings is a company with significant potential for growth in the spinal fusion technology market, but there are some fundamental risks that should be considered. While management has provided promising initial revenue guidance for 2026, achieving their long-term revenue target of $1 billion may prove challenging. Additionally, the company's margins may suffer from increased operating expenses and potential patent infringement lawsuits in the future. Overall, there is some potential upside for the company, but investors should carefully consider the risks before making any investment decisions.
This aggregate rating is based on analysts' research of Alphatec Hlds and is not a guaranteed prediction by Public.com or investment advice.
Alphatec Hlds (ATEC) Analyst Forecast & Price Prediction
Start investing in Alphatec Hlds (ATEC)
Order type
Buy in
Order amount
Est. shares
0 shares